The U.S. Food and Drug Administration announced today that it approved Amgen’s Xgeva to help prevent fractures and to slow bone disease in patients with solid tumors that have spread to and caused damage to bone. Xgeva was not approved, however, for multiple myeloma patients with bone damage.

Xgeva is the new brand name given to denosumab when used for the treatment of cancer-related bone disease. Denosumab at lower doses is marketed under the brand name Prolia for the treatment of postmenopausal women with osteoporosis and a high risk of bone fractures.

For more information, see the U.S. Food and Drug Administration website, and check back for further coverage on The Myeloma Beacon.

Update: Please see The Myeloma Beacon's full coverage.